Nirma-LafargeHolcim Rs 9,000 Crore Cement Deal Explained In 10 Points
Detergent maker Nirma on Monday announced that it will buy LafargeHolcim's India business for an enterprise value of around $1.4 billion (Rs 9,400 crore).
Here are 10 things to know about the Nirma-LafargeHolcim deal:
1) Ahmedabad-based Nirma will emerge as India's sixth largest cement manufacturer if the Rs 9,400 crore deal with LafargeHolcim goes through.
2) Nirma, a diversified group with presence in soaps, detergents, and soda ash among others, has a turnover of over Rs 7,300 crore. Nirma currently has 2 million tonnes per annum (mtpa) cement capacity in Rajasthan.
3) The Rs 9,400 crore Nirma-LafargeHolcim deal is the second largest in the cement space, after UltraTech Cement's acquisition of Jaypee Cement's assets for over Rs 16,000 crore.
4) Some analysts have termed the deal as costly, considering that UltraTech Cement acquired Jaypee Associates' 21.2 mtpa assets for $112 per tonne. In comparison, Nirma is paying $127 per tonne for LafargeHolcim's India assets.
5) Nirma will fund the deal through a mix of equity and debt. The company is likely to issue bonds worth Rs 4,000 crore to part-fund the acquisition.
6) Nirma bid aggressively to beat conglomerates like the Piramal Group and JSW Cement to win the LafargeHolcim deal.
7) Nirma will acquire Lafarge India's assets, which consist of three cement plants and two grinding stations with capacity of about 11 million tonnes a year.
8) The Nirma LafargeHolcim deal needs to be approved by the Competition Commission of India.
9) LafargeHolcim, the world's biggest cement maker, will use the proceeds of the deal to pare down its debt.
10) LafargeHolcim will continue to operate in India through its subsidiaries ACC and Ambuja Cements, which have a combined cement capacity of more than 60 million tonnes.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.